Topics in Current Chemistry, Journal Year: 2025, Volume and Issue: 383(2)
Published: March 13, 2025
Language: Английский
Acta Pharmaceutica Sinica B, Journal Year: 2023, Volume and Issue: 13(10), P. 4025 - 4059
Published: June 30, 2023
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads efficient killing, show great clinical therapeutic value. The ADCs' play a key role in determining efficacy ADC drugs thus have attracted attention field. An ideal payload should possess sufficient toxicity, low immunogenicity, high stability, modifiable functional groups. Common include tubulin inhibitors DNA damaging agents, accounting for more than half development. However, due to limitations traditional payloads, such as inadequate development acquired drug resistance, novel highly diverse targets reduced side effects are being developed. This perspective summarizes recent research advances main focuses on structure-activity relationship studies, co-crystal structures, designing strategies, further discusses future directions payloads. review also aims provide valuable references that will efficacy, adequate abilities overcome resistance.
Language: Английский
Citations
102
Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(5), P. 1965 - 1986
Published: Jan. 20, 2024
Bispecific antibody‒drug conjugates (BsADCs) represent an innovative therapeutic category amalgamating the merits of (ADCs) and bispecific antibodies (BsAbs). Positioned as next-generation ADC approach, BsADCs hold promise for ameliorating extant clinical challenges associated with ADCs, particularly pertaining to issues such poor internalization, off-target toxicity, drug resistance. Presently, ten are undergoing trials, initial findings underscore imperative ongoing refinement. This review initially delves into specific design considerations BsADCs, encompassing target selection, antibody formats, linker-payload complex. Subsequent sections delineate progress encountered by illustrated through pertinent case studies. The amalgamation BsAbs ADCs offers a prospective solution prevailing limitations ADCs. Nevertheless, symbiotic interplay among BsAb, linker, payload necessitates further optimizations coordination beyond simplistic "1 + 1" effectively surmount facing BsADC domain.
Language: Английский
Citations
34
European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 265, P. 116119 - 116119
Published: Jan. 1, 2024
Language: Английский
Citations
30
Heliyon, Journal Year: 2024, Volume and Issue: 10(4), P. e26009 - e26009
Published: Feb. 1, 2024
Drug-delivery systems (DDSs) are designed to deliver drugs their specific targets minimize toxic effects and improve susceptibility clearance during targeted transport. Peptides have high affinity, low immunogenicity, simple amino acid composition, adjustable molecular size; therefore, most peptides can be coupled via linkers form peptide-drug conjugates (PDCs) act as active pro-drugs. PDCs widely thought promising DDSs, given ability drug bio-compatibility physiological stability. Peptide-based DDSs often used therapeutic substances such anti-cancer nucleic acid-based drugs, which not only slow the degradation rate of in vivo but also ensure concentration at site prolong half-life vivo.This article provides an profile advancements future development functional peptide-based delivery both domestically internationally recent years, expectation achieving incorporating taking full advantage synergistic effects.
Language: Английский
Citations
19
ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(2), P. 309 - 334
Published: Jan. 24, 2024
The emergence of peptide–drug conjugates (PDCs) that utilize target-oriented peptide moieties as carriers cytotoxic payloads, interconnected with various cleavable/noncleavable linkers, resulted in the key-foundation new era targeted therapeutics. They are capable retaining integrity blood circulatory system well releasing drugs at tumor microenvironment. Other valuable advantages specificity and selectivity toward targeted-receptors, higher penetration ability, drug-loading capacity, making them a suitable candidate to play their vital role promising carrier agents. In this review, we summarized types cell-targeting (CTPs) cell-penetrating peptides (CPPs) have broad applications advancement drug-delivery systems (DDS). Moreover, techniques overcome limitations peptide-chemistry for extensive implementation construct PDCs. Besides this, diversified breakthrough linker chemistry, ample knowledge payloads used PDCs recent years, mechanism action was critically discussed. principal aim is provide scattered one place help researchers understand pinching knots science PDC development, also progression bright future novel theranostics clinical practice.
Language: Английский
Citations
18
Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(5), P. 674 - 674
Published: May 16, 2024
The escalating demand for enhanced therapeutic efficacy and reduced adverse effects in the pharmaceutical domain has catalyzed a new frontier of innovation research field pharmacy: novel drug delivery systems. These systems are designed to address limitations conventional administration, such as abbreviated half-life, inadequate targeting, low solubility, bioavailability. As disciplines pharmacy, materials science, biomedicine continue advance converge, development efficient safe systems, including biopharmaceutical formulations, garnered significant attention both domestically internationally. This article presents an overview latest advancements categorized into four primary areas: carrier-based coupling-based targeted intelligent devices, based on their main objectives methodologies. Additionally, it critically analyzes technological bottlenecks, current challenges, future trends application
Language: Английский
Citations
16
Medicinal Research Reviews, Journal Year: 2024, Volume and Issue: 44(6), P. 2420 - 2471
Published: May 5, 2024
The development of peptide drugs has made tremendous progress in the past few decades because advancements modification chemistry and analytical technologies. novel-designed have been modified through various biochemical methods with improved diagnostic, therapeutic, drug-delivery strategies. Researchers found it a helping hand to overcome inherent limitations peptides bring continued their applications. Furthermore, emergence peptide-drug conjugates (PDCs)-utilizes target-oriented moieties as vehicle for cytotoxic payloads via conjugation cleavable chemical agents, resulting key foundation new era targeted drugs. This review summarizes classifications drugs, suitable strategies improve ADME (adsorption, distribution, metabolism, excretion) features recent (2015-early 2024) progress/achievements peptide-based drug delivery systems well fruitful implication preclinical clinical studies. we also summarized brief description other types PDCs, including peptide-MOF peptide-UCNP conjugates. principal aim is provide scattered diversified knowledge one place help researchers understand pinching knots science PDC toward bright future novel
Language: Английский
Citations
11
European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 276, P. 116709 - 116709
Published: July 25, 2024
Language: Английский
Citations
11
Advanced Science, Journal Year: 2024, Volume and Issue: 11(21)
Published: March 11, 2024
Abstract Peptide and protein postmodification have gained significant attention due to their extensive impact on biomolecule engineering drug discovery, of which cysteine‐specific modification strategies are prominent inherent nucleophilicity low abundance. Herein, the study introduces a novel approach utilizing multifunctional 5‐substituted 1,2,3‐triazine derivatives achieve multifaceted bioconjugation targeting cysteine‐containing peptides proteins. On one hand, this represents an inaugural instance employing in biomolecular‐specific within physiological solution. other as powerful combination precision biorthogonality, strategy allows for one‐pot dual‐orthogonal functionalization biomolecules aldehyde group generated simultaneously. 1,2,3‐Triazine with diverse functional groups allow conjugation or proteins, while bi‐triazines enable peptide cyclization dimerization. The examination stability revealed potential reversible modification. This work establishes comprehensive platform identifying cysteine‐selective modifications, providing new avenues peptide‐based development, bioconjugation, chemical biology research.
Language: Английский
Citations
10
Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 67(14), P. 11469 - 11487
Published: July 9, 2024
Antibody-drug conjugates (ADCs) comprise antibodies, cytotoxic payloads, and linkers, which can integrate the advantages of antibodies small molecule drugs to achieve targeted cancer treatment. However, ADCs also have some shortcomings, such as non-negligible drug resistance, a low therapeutic index, payload-related toxicity. Many studies focused on changing composition ADCs, even further extended concept types conjugated by replacing in with peptides, revolutionarily introducing peptide-drug (PDCs). This Perspective summarizes current research status PDCs highlights structural innovations ADC components. In particular, are regarded next generation potential after challenges analyzed. Our aim is offer fresh insights for efficient design expedited development innovative drugs.
Language: Английский
Citations
8